Doxorubicin, the drug of choice in breast cancer, induces metastasis through activation of the TGFβ signaling pathway to trigger Epithelial-mesenchymal transition (EMT) (Bandyopadhyay et al., 2010). This evidence concerns the gene TGFB1 and breast cancer.